Expert Interview
Discussing the commercial outlook of Coherus' Cimerli (ranibizumab biosimilar) and Outlook's Lytenava (ophthalmic formulation of bevacizumab) in Wet AMD
Ticker(s): CHRS, OTLKInstitution: Duke Eye Center
- treats 500 patients with geographic atrophy.
- Very familiar with the potential use of intravitreal pegcetacoplan for geographic atrophy
- has seen the publicly available data for both the Phase 2 and Phase 3 data supporting development of pegcetacoplan for treatment of GA and is familiar with the recently released 24-month results of pegcetacoplan in Phase 3 DERBY and OAKS Studies
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
